Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-09

AUTHORS

O. Pagani, M. Zucchetti, C. Sessa, J. de Jong, M. D’Incalci, M. De Fusco, A. Kaeser-Fröhlich, A. Hanauske, F. Cavalli

ABSTRACT

NK611 is a novel water-soluble podophyllotoxin derivative that has comparable antitumour activity but higher potency and better bioavailability in animals as compared with etoposide. The primary objectives of this study were to determine, after both oral and intravenous administration in the same patient, the bioavailability and the pharmacokinetic profile of NK611. Secondary objectives involved evaluation of the toxicity and the antitumor activity. Patients were randomly assigned to receive oral or intravenous (30-min infusion) doses of 5, 10, and 20 mg/m2 on day 1, when pharmacokinetic studies were performed. A daily oral dose of 20 mg/m2 was then given from day 4 through day 7 for respective total doses of 85, 90, and 100 mg/m2. NK611 and its metabolites were determined in plasma and urine by two different high-performance liquid chromatography (HPLC) methods with UV detection. A total of 21 adult patients entered the study and received the complete first cycle and at least the 1st day of cycle 2; 17 of them received at least 2 complete cycles of treatment. After intravenous administration, the plasma decay curve of NK611 followed a two-exponential model, and after oral administration it declined monoexponentially in most cases. At all dose levels, bioavailability values were around 100%. At concentrations between 10 and 20 mg/m2 after both routes of administration, the pharmacokinetics were nonlinear; the terminal half-life, plasma clearance, and volume of distribution were significantly different; and the area under the plasma concentration-time curve was not correlated to the dose. The urinary excretion of NK611 corresponded to 10-15% of the dose after administration by both routes, whereas that of N-demethyl NK611 and its picroform was highly variable. The features of neutropenia were comparable with those noted for etoposide involving a high degree of interpatient variability and recovery within 1 month after treatment. A daily dose of 20 mg/m2 for 5 consecutive days every 4 weeks is the recommended regimen for phase II studies in patients who have never been treated or have undergone previous chemotherapy only once. More... »

PAGES

541-547

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002800050524

DOI

http://dx.doi.org/10.1007/s002800050524

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047341901

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/8823496


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenal Gland Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Podophyllotoxin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombocytopenia", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ospedale San Giovanni Bellinzona", 
          "id": "https://www.grid.ac/institutes/grid.415065.3", 
          "name": [
            "Servizio Oncologico Cantonale, Ospedale San Giovanni, CH-6500 Bellinzona, Switzerland, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pagani", 
        "givenName": "O.", 
        "id": "sg:person.01020005374.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020005374.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mario Negri Institute for Pharmacological Research", 
          "id": "https://www.grid.ac/institutes/grid.4527.4", 
          "name": [
            "Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zucchetti", 
        "givenName": "M.", 
        "id": "sg:person.0720105551.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720105551.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Giovanni Bellinzona", 
          "id": "https://www.grid.ac/institutes/grid.415065.3", 
          "name": [
            "Servizio Oncologico Cantonale, Ospedale San Giovanni, CH-6500 Bellinzona, Switzerland, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sessa", 
        "givenName": "C.", 
        "id": "sg:person.014032514774.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014032514774.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Giovanni Bellinzona", 
          "id": "https://www.grid.ac/institutes/grid.415065.3", 
          "name": [
            "Servizio Oncologico Cantonale, Ospedale San Giovanni, CH-6500 Bellinzona, Switzerland, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Jong", 
        "givenName": "J.", 
        "id": "sg:person.01200564402.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200564402.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mario Negri Institute for Pharmacological Research", 
          "id": "https://www.grid.ac/institutes/grid.4527.4", 
          "name": [
            "Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "D\u2019Incalci", 
        "givenName": "M.", 
        "id": "sg:person.010326374464.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010326374464.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mario Negri Institute for Pharmacological Research", 
          "id": "https://www.grid.ac/institutes/grid.4527.4", 
          "name": [
            "Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fusco", 
        "givenName": "M. De", 
        "id": "sg:person.01370120420.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370120420.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evonik (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420017.0", 
          "name": [
            "Asta Medica AG, Frankfurt, Germany, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaeser-Fr\u00f6hlich", 
        "givenName": "A.", 
        "id": "sg:person.01215301435.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215301435.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinikum der Universit\u00e4t M\u00fcnchen", 
          "id": "https://www.grid.ac/institutes/grid.411095.8", 
          "name": [
            "Division of Hematology and Oncology, University Hospital, M\u00fcnchen, XX"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanauske", 
        "givenName": "A.", 
        "id": "sg:person.01114224637.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114224637.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Giovanni Bellinzona", 
          "id": "https://www.grid.ac/institutes/grid.415065.3", 
          "name": [
            "Servizio Oncologico Cantonale, Ospedale San Giovanni, CH-6500 Bellinzona, Switzerland, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cavalli", 
        "givenName": "F.", 
        "id": "sg:person.01261712265.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261712265.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0277-5379(85)90310-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019281113"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-4347(93)e0453-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033050826"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0010-468x(83)90006-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048030318"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0010-468x(83)90006-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048030318"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049278910"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1993.11.2.374", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082801880"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1996-09", 
    "datePublishedReg": "1996-09-01", 
    "description": "NK611 is a novel water-soluble podophyllotoxin derivative that has comparable antitumour activity but higher potency and better bioavailability in animals as compared with etoposide. The primary objectives of this study were to determine, after both oral and intravenous administration in the same patient, the bioavailability and the pharmacokinetic profile of NK611. Secondary objectives involved evaluation of the toxicity and the antitumor activity. Patients were randomly assigned to receive oral or intravenous (30-min infusion) doses of 5, 10, and 20 mg/m2 on day 1, when pharmacokinetic studies were performed. A daily oral dose of 20 mg/m2 was then given from day 4 through day 7 for respective total doses of 85, 90, and 100 mg/m2. NK611 and its metabolites were determined in plasma and urine by two different high-performance liquid chromatography (HPLC) methods with UV detection. A total of 21 adult patients entered the study and received the complete first cycle and at least the 1st day of cycle 2; 17 of them received at least 2 complete cycles of treatment. After intravenous administration, the plasma decay curve of NK611 followed a two-exponential model, and after oral administration it declined monoexponentially in most cases. At all dose levels, bioavailability values were around 100%. At concentrations between 10 and 20 mg/m2 after both routes of administration, the pharmacokinetics were nonlinear; the terminal half-life, plasma clearance, and volume of distribution were significantly different; and the area under the plasma concentration-time curve was not correlated to the dose. The urinary excretion of NK611 corresponded to 10-15% of the dose after administration by both routes, whereas that of N-demethyl NK611 and its picroform was highly variable. The features of neutropenia were comparable with those noted for etoposide involving a high degree of interpatient variability and recovery within 1 month after treatment. A daily dose of 20 mg/m2 for 5 consecutive days every 4 weeks is the recommended regimen for phase II studies in patients who have never been treated or have undergone previous chemotherapy only once.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s002800050524", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "name": "Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative", 
    "pagination": "541-547", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e18581ef7e93def85ed5524114ff2600cac0c75cc5d390cc75229a712a06a2c5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "8823496"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002800050524"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047341901"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002800050524", 
      "https://app.dimensions.ai/details/publication/pub.1047341901"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000483.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s002800050524"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002800050524'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002800050524'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002800050524'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002800050524'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      21 PREDICATES      55 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002800050524 schema:about N0806941dd1dc4e5ea788015521dd18ec
2 N0916d5eac7fb48699008359566eeded6
3 N0c3b745dab3a451e849b91cc50c37e40
4 N1075a8bbb95f470ca28bf49ae6891242
5 N17174c96322e49d4a92b54d4bdf35e12
6 N241385883f85409b9c6df620d3c97cb5
7 N28472491373748aa9bfd6c35041a4db2
8 N3013d93dcb4a469eaa7dc835246c26f1
9 N43a6994574c54c89a11b86f314a1d736
10 N50af1e3f13394d4e91ceddfb60bec3ba
11 N51a72b6dcb9a4cd5baaa3ee6ef9e9362
12 N51cb70a10e2d4119b3438c2cc3b264f9
13 N5a58b232135a40fbaecbdc9fb2ae2cde
14 N75ac4f32127f4b89982f1bd17f881275
15 N871de3076f3548f4a945292b7dda0f25
16 Nac824f6ae9aa4c04a337c8120c52784a
17 Nad5789c9bdcd41b99d3db5d7bed5217f
18 Ncecf91e1cc95466f9c862b182f5a5614
19 Nedccf1f2722f44c8a443aa4669e84d05
20 Nf5f8cd532285435fba68063d27c29f75
21 Nff18b3cde24f4968b13e1800344dc06c
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author N48fee98c3a8748338dc541d5e0dd64c2
25 schema:citation https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6
26 https://doi.org/10.1016/0010-468x(83)90006-5
27 https://doi.org/10.1016/0277-5379(85)90310-4
28 https://doi.org/10.1016/0378-4347(93)e0453-w
29 https://doi.org/10.1200/jco.1993.11.2.374
30 schema:datePublished 1996-09
31 schema:datePublishedReg 1996-09-01
32 schema:description NK611 is a novel water-soluble podophyllotoxin derivative that has comparable antitumour activity but higher potency and better bioavailability in animals as compared with etoposide. The primary objectives of this study were to determine, after both oral and intravenous administration in the same patient, the bioavailability and the pharmacokinetic profile of NK611. Secondary objectives involved evaluation of the toxicity and the antitumor activity. Patients were randomly assigned to receive oral or intravenous (30-min infusion) doses of 5, 10, and 20 mg/m2 on day 1, when pharmacokinetic studies were performed. A daily oral dose of 20 mg/m2 was then given from day 4 through day 7 for respective total doses of 85, 90, and 100 mg/m2. NK611 and its metabolites were determined in plasma and urine by two different high-performance liquid chromatography (HPLC) methods with UV detection. A total of 21 adult patients entered the study and received the complete first cycle and at least the 1st day of cycle 2; 17 of them received at least 2 complete cycles of treatment. After intravenous administration, the plasma decay curve of NK611 followed a two-exponential model, and after oral administration it declined monoexponentially in most cases. At all dose levels, bioavailability values were around 100%. At concentrations between 10 and 20 mg/m2 after both routes of administration, the pharmacokinetics were nonlinear; the terminal half-life, plasma clearance, and volume of distribution were significantly different; and the area under the plasma concentration-time curve was not correlated to the dose. The urinary excretion of NK611 corresponded to 10-15% of the dose after administration by both routes, whereas that of N-demethyl NK611 and its picroform was highly variable. The features of neutropenia were comparable with those noted for etoposide involving a high degree of interpatient variability and recovery within 1 month after treatment. A daily dose of 20 mg/m2 for 5 consecutive days every 4 weeks is the recommended regimen for phase II studies in patients who have never been treated or have undergone previous chemotherapy only once.
33 schema:genre research_article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N4cc7f8091ce14efa91e7c238cf995c8d
37 Nd0e520464bc149b7833b44606ef9794d
38 sg:journal.1088364
39 schema:name Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative
40 schema:pagination 541-547
41 schema:productId N1387f12c21ac46a69aa75c0e1b80bf7e
42 N3b9b774242874bc19ab025877d741f46
43 N5c927b9e32bf4b19a135242e2d418af4
44 N9b5d52c14ebd4be290d5f2f0d45df633
45 Na141efb4756d4ec7bbb040a51aadc6de
46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047341901
47 https://doi.org/10.1007/s002800050524
48 schema:sdDatePublished 2019-04-10T14:01
49 schema:sdLicense https://scigraph.springernature.com/explorer/license/
50 schema:sdPublisher N885846ad5a054500baf6d6418558067d
51 schema:url http://link.springer.com/10.1007/s002800050524
52 sgo:license sg:explorer/license/
53 sgo:sdDataset articles
54 rdf:type schema:ScholarlyArticle
55 N0806941dd1dc4e5ea788015521dd18ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
56 schema:name Bone Neoplasms
57 rdf:type schema:DefinedTerm
58 N0916d5eac7fb48699008359566eeded6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Adult
60 rdf:type schema:DefinedTerm
61 N0c3b745dab3a451e849b91cc50c37e40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Thrombocytopenia
63 rdf:type schema:DefinedTerm
64 N1075a8bbb95f470ca28bf49ae6891242 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Aged
66 rdf:type schema:DefinedTerm
67 N1209a1adf832476096150d7ae1d61b0c rdf:first sg:person.01370120420.31
68 rdf:rest Nff87459b5c914c999b2332cefe983c16
69 N1301a062b7fc4de8a6f8fec1c9132e24 rdf:first sg:person.01261712265.09
70 rdf:rest rdf:nil
71 N1387f12c21ac46a69aa75c0e1b80bf7e schema:name pubmed_id
72 schema:value 8823496
73 rdf:type schema:PropertyValue
74 N17174c96322e49d4a92b54d4bdf35e12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Disease Progression
76 rdf:type schema:DefinedTerm
77 N1e32eba18a43464dbd1a9f60c9f0f4d8 rdf:first sg:person.010326374464.29
78 rdf:rest N1209a1adf832476096150d7ae1d61b0c
79 N241385883f85409b9c6df620d3c97cb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Carcinoma, Non-Small-Cell Lung
81 rdf:type schema:DefinedTerm
82 N28472491373748aa9bfd6c35041a4db2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Neutropenia
84 rdf:type schema:DefinedTerm
85 N3013d93dcb4a469eaa7dc835246c26f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Drug Administration Schedule
87 rdf:type schema:DefinedTerm
88 N3b9b774242874bc19ab025877d741f46 schema:name dimensions_id
89 schema:value pub.1047341901
90 rdf:type schema:PropertyValue
91 N43a6994574c54c89a11b86f314a1d736 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Adrenal Gland Neoplasms
93 rdf:type schema:DefinedTerm
94 N48fee98c3a8748338dc541d5e0dd64c2 rdf:first sg:person.01020005374.76
95 rdf:rest Nea3529337db14d7fba49bcb8bced1d1e
96 N4cc7f8091ce14efa91e7c238cf995c8d schema:volumeNumber 38
97 rdf:type schema:PublicationVolume
98 N50af1e3f13394d4e91ceddfb60bec3ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Administration, Oral
100 rdf:type schema:DefinedTerm
101 N51a72b6dcb9a4cd5baaa3ee6ef9e9362 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Neoplasms
103 rdf:type schema:DefinedTerm
104 N51cb70a10e2d4119b3438c2cc3b264f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Area Under Curve
106 rdf:type schema:DefinedTerm
107 N5a58b232135a40fbaecbdc9fb2ae2cde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Biological Availability
109 rdf:type schema:DefinedTerm
110 N5c927b9e32bf4b19a135242e2d418af4 schema:name doi
111 schema:value 10.1007/s002800050524
112 rdf:type schema:PropertyValue
113 N6aed382168eb489a8e839be82b326bd1 rdf:first sg:person.01200564402.69
114 rdf:rest N1e32eba18a43464dbd1a9f60c9f0f4d8
115 N75ac4f32127f4b89982f1bd17f881275 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Male
117 rdf:type schema:DefinedTerm
118 N871de3076f3548f4a945292b7dda0f25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Female
120 rdf:type schema:DefinedTerm
121 N885846ad5a054500baf6d6418558067d schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 N8de96165d98a422b9ba659a138b5aab1 rdf:first sg:person.01114224637.79
124 rdf:rest N1301a062b7fc4de8a6f8fec1c9132e24
125 N91d997b449db4d108a49e2d1829c9043 rdf:first sg:person.014032514774.66
126 rdf:rest N6aed382168eb489a8e839be82b326bd1
127 N9b5d52c14ebd4be290d5f2f0d45df633 schema:name readcube_id
128 schema:value e18581ef7e93def85ed5524114ff2600cac0c75cc5d390cc75229a712a06a2c5
129 rdf:type schema:PropertyValue
130 Na141efb4756d4ec7bbb040a51aadc6de schema:name nlm_unique_id
131 schema:value 7806519
132 rdf:type schema:PropertyValue
133 Nac824f6ae9aa4c04a337c8120c52784a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Humans
135 rdf:type schema:DefinedTerm
136 Nad5789c9bdcd41b99d3db5d7bed5217f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Lung Neoplasms
138 rdf:type schema:DefinedTerm
139 Ncecf91e1cc95466f9c862b182f5a5614 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Middle Aged
141 rdf:type schema:DefinedTerm
142 Nd0e520464bc149b7833b44606ef9794d schema:issueNumber 6
143 rdf:type schema:PublicationIssue
144 Nea3529337db14d7fba49bcb8bced1d1e rdf:first sg:person.0720105551.12
145 rdf:rest N91d997b449db4d108a49e2d1829c9043
146 Nedccf1f2722f44c8a443aa4669e84d05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Podophyllotoxin
148 rdf:type schema:DefinedTerm
149 Nf5f8cd532285435fba68063d27c29f75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Injections, Intravenous
151 rdf:type schema:DefinedTerm
152 Nff18b3cde24f4968b13e1800344dc06c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Antineoplastic Agents
154 rdf:type schema:DefinedTerm
155 Nff87459b5c914c999b2332cefe983c16 rdf:first sg:person.01215301435.50
156 rdf:rest N8de96165d98a422b9ba659a138b5aab1
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
161 schema:name Clinical Sciences
162 rdf:type schema:DefinedTerm
163 sg:journal.1088364 schema:issn 0344-5704
164 1432-0843
165 schema:name Cancer Chemotherapy and Pharmacology
166 rdf:type schema:Periodical
167 sg:person.01020005374.76 schema:affiliation https://www.grid.ac/institutes/grid.415065.3
168 schema:familyName Pagani
169 schema:givenName O.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020005374.76
171 rdf:type schema:Person
172 sg:person.010326374464.29 schema:affiliation https://www.grid.ac/institutes/grid.4527.4
173 schema:familyName D’Incalci
174 schema:givenName M.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010326374464.29
176 rdf:type schema:Person
177 sg:person.01114224637.79 schema:affiliation https://www.grid.ac/institutes/grid.411095.8
178 schema:familyName Hanauske
179 schema:givenName A.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114224637.79
181 rdf:type schema:Person
182 sg:person.01200564402.69 schema:affiliation https://www.grid.ac/institutes/grid.415065.3
183 schema:familyName de Jong
184 schema:givenName J.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200564402.69
186 rdf:type schema:Person
187 sg:person.01215301435.50 schema:affiliation https://www.grid.ac/institutes/grid.420017.0
188 schema:familyName Kaeser-Fröhlich
189 schema:givenName A.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215301435.50
191 rdf:type schema:Person
192 sg:person.01261712265.09 schema:affiliation https://www.grid.ac/institutes/grid.415065.3
193 schema:familyName Cavalli
194 schema:givenName F.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261712265.09
196 rdf:type schema:Person
197 sg:person.01370120420.31 schema:affiliation https://www.grid.ac/institutes/grid.4527.4
198 schema:familyName Fusco
199 schema:givenName M. De
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370120420.31
201 rdf:type schema:Person
202 sg:person.014032514774.66 schema:affiliation https://www.grid.ac/institutes/grid.415065.3
203 schema:familyName Sessa
204 schema:givenName C.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014032514774.66
206 rdf:type schema:Person
207 sg:person.0720105551.12 schema:affiliation https://www.grid.ac/institutes/grid.4527.4
208 schema:familyName Zucchetti
209 schema:givenName M.
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720105551.12
211 rdf:type schema:Person
212 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049278910
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1016/0010-468x(83)90006-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048030318
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/0277-5379(85)90310-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019281113
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/0378-4347(93)e0453-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1033050826
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1200/jco.1993.11.2.374 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082801880
221 rdf:type schema:CreativeWork
222 https://www.grid.ac/institutes/grid.411095.8 schema:alternateName Klinikum der Universität München
223 schema:name Division of Hematology and Oncology, University Hospital, München, XX
224 rdf:type schema:Organization
225 https://www.grid.ac/institutes/grid.415065.3 schema:alternateName Ospedale San Giovanni Bellinzona
226 schema:name Servizio Oncologico Cantonale, Ospedale San Giovanni, CH-6500 Bellinzona, Switzerland, CH
227 rdf:type schema:Organization
228 https://www.grid.ac/institutes/grid.420017.0 schema:alternateName Evonik (Germany)
229 schema:name Asta Medica AG, Frankfurt, Germany, DE
230 rdf:type schema:Organization
231 https://www.grid.ac/institutes/grid.4527.4 schema:alternateName Mario Negri Institute for Pharmacological Research
232 schema:name Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy, IT
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...